Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Efficacy of two one‐week rabeprazole/levofloxacin‐based triple therapies for Helicobacter pylori infection

Open access
Cammarota, G., Cianci, R., Cannizzaro, O., Cuoco, L., Pirozzi, G., Gasbarrini, A., Armuzzi, A., Zocco, M. A., Santarelli, L., Arancio, F., Gasbarrini, G. · 2000 · Alimentary Pharmacology & Therapeutics

Abstract

Background: One‐week low‐dose proton pump inhibitor‐based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection. Aim: To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluoroquinolone, levofloxacin. Methods: One hundred patients referred to us for gastroscopy, who were H. pylori‐positive, were consecutively recruited in a prospective, open‐label study. The enrolled patients were randomised to receive a seven‐day course of rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and either amoxycillin 1 g b.d. (RLA group) or tinidazole 500 mg b.d. (RLT group). Their H. pylori status was assessed by means of histology and rapid urease test at entry, and by 13 C‐urea breath test 8 weeks after the end of treatment. Results: All 100 enrolled patients completed the study. Forty‐six of 50 patients treated with RLA (both PP and ITT analysis: 92%; 95% CI: 81–98%) and 45 of 50 with RLT (both PP and ITT analysis: 90%: 95% CI: 78–97%), became H. pylori‐negative. Slight or mild side‐effects occurred in 4 (8%) patients of the RLA group and in 5 (10%) of the RLT group. Conclusions: This study demonstrates the efficacy of two 1‐week rabeprazole‐based triple therapies including levofloxacin to eradicate H. pylori. These regimens prove to be safe, well‐tolerated, and achieved good eradication rates. Levofloxacin may be an effective alternative to clarithromycin in triple therapy regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2000.00846.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 160

Metadata

Authors
Cammarota, G., Cianci, R., Cannizzaro, O., Cuoco, L., Pirozzi, G., Gasbarrini, A., Armuzzi, A., Zocco, M. A., Santarelli, L., Arancio, F., & Gasbarrini, G.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2000-10
Volume
14
Issue
10
Pages
1339-1343
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1981314660
Cited by
160
References
1
FWCI
10.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of two one‐week rabeprazole/levofloxacin‐based triple therapies for Helicobacter pylori infection. https://app.cochat.ai/papers/10.1046/j.1365-2036.2000.00846.x
The paper
Cammarota, G., Cianci, R., Cannizzaro, O., Cuoco, L., Pirozzi, G., Gasbarrini, A., Armuzzi, A., Zocco, M. A., Santarelli, L., Arancio, F., & Gasbarrini, G. (2000). Efficacy of two one‐week rabeprazole/levofloxacin‐based triple therapies for Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2000.00846.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.